New technologies delivered to your inbox Subscribe
Browse by Category
With hundreds of new disclosures each year from every facet of Mayo Clinic’s practice, Mayo Clinic Ventures is always looking for partners to help bring these inventions to the marketplace. Find specific technologies by searching with keywords above or by browsing in the categories to the right. We also provide summaries of selected technologies and their stages of development in the following sectors:
2017-284 – Humanized PD-1, B7-H1 (PD-L1) and combination PD-1/B7-H1 (PD-L1) Knock-In Mouse Models Mayo Clinic researchers have produced humanized PD-1 and B7-H1 (PD-L1) mice using a homozygous “knock-in” strategy to meet the need for an in vivo model that can be used in the development of safe and effective drugs targeting PD-1 and B7-H1. The exons encoding the ligand binding extracellular Ig like... Read More
2013-157 – Application Enhance transduction and transgene expression of Adeno-associated virus (AAV) vectors using U2 snRNP spliceosome inhibitors Value Proposition AAV has become one of the leading gene delivery vectors in clinical development. Gene therapy using recombinant AAV has been demonstrated to be safe and well-tolerated in virtually every clinical setting in which it has been used.... Read More
2016-372 – Mayo Clinic Researchers have discovered that microbiome associated protein 1 (MAP1)B1 is the antigen for PCA-2 autoantibodeis.
2015-347 – Mayo Clinic has developed compositions and methods for detecting soluble PD-L1
2015-311 – Mayo Clinic has discovered that HEATR1 is a novel Akt regulator and a predictor for chemoradioresistance.
2015-312 – Mayo Clinic has discovered that the Parkin protein is a mitotic regulator. Cancer cells with deficiency or mutations in Parkin have an increase in mitotic regulator expression leading to tumorigenesis and an increase in sensitivity of Pk1 and Aurora kinase inhibitors. This newly identified mechanism has revealed that Parkin mutations may be used as a biomarker for measuring the sensitivity of... Read More
2015-164 – Mayo Clinic has discovered that WSB1 can be used as a diagnostic marker for tumor metastasis and a therapeutic target.
2013-237 – Bim is a biomarker for PD-1 and PD-L1 therapies.
Methods of Treating Cancer by Using PD1 and PD-L1 inhibitors by Using Soluble PD-L1 Levels as a Biomarker
2008-042 – Mayo Clinic has patent rights claiming methods of using PD1 or PD-L1 antibodies to treat cancer by using soluble PD-L1 levels in the serum as a biomarker.
2004-222 – Mayo Clinic has patent rights claiming obesity devices.